Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

NewAmsterdam Pharma Co N.V.

NASDAQ: NAMS · Life Sciences · 5 alerts · CIK 1936258

Share price
$19.46Close, Nov 16
Market cap
$2.33B
Shares outstanding
119.93MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All NewAmsterdam Pharma Co N.V. filings on SEC EDGAR ↗

8:23 AM ET 8-K
Business Update

NewAmsterdam Pharma Co Business Update

NewAmsterdam Pharma has dosed the first participant in its Phase 2b SPINOZA clinical trial, which evaluates obicetrapib in approximately 400 individuals with preclinical Alzheimer’s disease. The study will assess changes in blood-based biomarkers and cognitive measures over a 52-week treatment period. This expansion into Alzheimer's follows biomarker signals observed in the company's Phase 3 BROADWAY trial.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.